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Merkel cell polyomavirus (MCV) has been recently described
as the cause for most human Merkel cell carcinomas. MCV is
similar to simian virus 40 (SV40) and encodes a nuclear large T
(LT) oncoprotein that is usually mutated to eliminate viral rep-
lication among tumor-derivedMCV.We identified the hVam6p
cytoplasmic protein involved in lysosomal processing as a novel
interactor with MCV LT but not SV40 LT. hVam6p binds
through its clathrin heavy chain homology domain to a unique
region of MCV LT adjacent to the retinoblastoma binding site.
MCV LT translocates hVam6p to the nucleus, sequestering it
from involvement in lysosomal trafficking. A naturally occur-
ring, tumor-derived mutant LT (MCV350) lacking a nuclear
localization signal binds hVam6p but fails to inhibit hVam6p-
induced lysosomal clustering. MCV has evolved a novel mecha-
nism to target hVam6p thatmay contribute to viral uncoating or
egress through lysosomal processing during virus replication.
Merkel cell polyomavirus (MCV)5 is a newly discovered
human polyomavirus detected in 80% of Merkel cell carcino-
mas (MCC) (1, 2).MCV encodes large T (LT), small T (ST), and
57kT transcripts similar to those of SV40 (2). These MCV T
antigen sequences retain motifs found in other polyomavirus T
antigens known to cause oncogenic transformation of rodent
cells, such as an LXCXE (LFCDE) motif that binds to the reti-
noblastoma family of proteins and aDnaJ domain that interacts
with heat-shock proteins (3–5). Significant mechanistic in-
sights have been gained by identifying and characterizing cel-
lular proteins that associate with polyomavirus T antigens. In
addition to pRB and Hsc70, other cellular proteins linked to
neoplastic transformation that interact with various T antigens
include p53, Cul7, Bub1, PP2A, PI 3-kinase, and Shc (3, 4,
6–13). Identifying novel MCV T antigen binding partners is
likely to provide critical insights into the mechanisms underly-
ing MCV-induced tumorigenesis or viral replication.
MCV tumor-derived LTs have stop codon mutations that
eliminate the helicase/ATPase domain but spare N-terminal
LXCXE andDnaJ domains (2). Compared with SV40 T antigen,
however, MCV T antigen contains a distinct 200-amino acid
region, that we term theMCVT antigen unique region (MUR).
MUR is located between the first exon and the origin-binding
domain, and is conserved among tumor-derived MCV strains
(14). AlthoughMUR contains a partially conserved Bub1 bind-
ing motif similar that of SV40 LT (8), Bub1 does not appear to
interact with MCV LT.6 There are no other obvious features of
MUR that might indicate its function for the virus.
We identified human Vam6p (hVam6p) by tandem-affinity
pull-down of cellular proteins with a tagged MUR protein
sequence. hVam6p is a cytoplasmic protein that promotes lyso-
some clustering and fusion in vivo through citron homology
(CNH) and clathrin heavy chain repeat (CLH) domains (15).
hVam6p also exhibits homology to the Saccharomyces cerevi-
siae vacuolar protein sorting 39 protein (Vps39). In yeast,mem-
brane tethering is orchestrated at endosomes by the class C
core vacuole/endosome transport (CORVET) complex and at
lysosomes by the homotypic fusion and vacuole protein sorting
(HOPS) complex. The HOPS complex is composed of the class
C Vps complex (Vps11, Vps33, Vps18, Vps16) present in
CORVET as well as Vps39 and Vps41 (16). Individual subunits
appear to be conserved inmammalian cells. In addition to lyso-
somal metabolism, isoforms of hVam6p play roles in trans-
forming growth factor- (TGF-) and mTOR signaling.
hVam6p has been reported to be identical to an isoform of the
TRAP-1-like protein that regulates the balance between Smad2
and Smad3 signaling through Smad4 interactions (17). Vam6/
Vps39 in yeast has been shown to be a guanine nucleotide
exchange factor for Gtr1, a Rag family GTPase that promotes
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TORC1 activation in response to amino acid availability (18). In
mammalian cells, hVam6p has been proposed to regulate
mTORC1 signaling (19).
In this studywe show thatMCVLTbinds hVam6p through a
domain adjacent to the Rb-binding LXCXE motif and seques-
ters cytoplasmic hVam6p to the nucleus. This interaction is
unique toMCV and does not occur with SV40 LT.Mislocaliza-
tion of hVam6p by MCV LT inhibits hVam6p-induced lyso-
some clustering but does not have readily identifiable effects on
TGF- or mTOR signaling. This study shows that MCV mod-
ulates lysosomal clustering through a novel nuclear sequestra-
tion mechanism.
EXPERIMENTAL PROCEDURES
Plasmids—For generation of pNTAP-T4 and pNTAP-T5,
theMCV sequence was amplified from the 5 RACE product of
MCV genomic LT (pcDNA3.1.MCV350) using primers
MCV.861.BglII.S, 5-GG AGA TCT AGT TGA CGA GGC
CCC TAT ATA TGG G-3; Exon2.1565.XhoI.AS, 5-CG CTC
GAG AGT AGG AAC AGG AGT TTC TCT G-3;
MCV.196.BglII.S, 5-C GGG AGA TCT GGA TTT AGT CCT
AAA TAG GAA AGA AAG-3; Exon2.1565.XhoI.AS, 5-CG
CTC GAG AGT AGG AAC AGG AGT TTC TCT G-3. The
BglII/XhoI-digested fragments were cloned into pNTAP-B
(Stratagene) using BamHI and XhoI restriction sites.
pcDNA3.1.MCV350was generated usingMCC350 tissue DNA
as template and primers 350.FLT.KpnI.F2.S, 5-GG GGT ACC
CAG CTC ATT TGC TCC TCT GCT G TT TCT-3 and
350.FLT.XhoI.R, 5-CCG CTC GAG CGG TGG GTC TAT
TCAGACAGGCTCT-3. The PCRproductwas digestedwith
KpnI/XhoI and cloned into pcDNA3.1/Zeo vector (Invitrogen).
To generate pNTAP-SV40.T1–136, pCMV.SV40.LT was
amplified using primers T1–136.S, 5-CCT TTA GGA TCC
GCC ATG GAT AAA GTT TTA AAC AGA-3, and
T1–136.AS, 5-CCT TTA GGA TCC TTA CTT GGG GTC
TTC TAC C-3. The PCR product was digested with BamHI
and cloned into pNTAP-B (Stratagene). Construction of gLT-
V5, LT-V5, cLT339-V5, and cLT350-V5 expression plasmids
were described previously (2). LT-EGFP, cLT339-EGFP, and
cLT350-EGFP were constructed using inserts from LT-V5,
cLT339-V5, and cLT350-V5 digested with NheI/SacII and
cloned into pEGFP-N1 (Clontech). SV40.LT-EGFP was ampli-
fied from pCMV.SV40.LT and cloned into pEGFP-N1
(Clontech).
To generate GST fusion MCV LT truncations GST-LT(1–
258), GST-LT(79–170), GST-LT(171–258), GST-LT(171–
218), and GST-LT(219–258), pcDNA6.LT-V5 (2) were ampli-
fied using primers: pGEX.LT.1–78.BglII(S), 5-CCTTTAAGA
TCT GCC ATG GAT TTA GTC CTA AAT AGG-3 and
pGEX.LT.1–258.BglII(AS), 5-CCTTTAAGATCTTTAATC
TGT AAA CTG AGA TGA CG-3; pGEX.LT.79–258.BglII.S,
5-CCTTTAAGATCTGCCGTTGACGAGGCCCCTATA
TAT GGG-3; pGEX.LT.79–170.BglII.AS, 5-CCT TTA AGA
TCT TTA TTC CTC ATG GTG TTC GGG AGG-3;
pGEX.LT.171–258.BglII.S, 5-CCTTTAAGATCTGCCCCC
ACCTCATCCTCTGGATCC-3; pGEX.LT.1–258.BglII.AS,
5-CCTTTAAGATCTTTAATCTGTAAACTGAGATGA
CG-3; pGEX.LT.171–258.BglII.S, 5-CCT TTA AGA TCT
GCCCCCACCTCATCCTCTGGATCC-3; pGEX.LT.171–
218.BglII.AS, 5-CCT TTA AGA TCT TTA AAG TGA TTC
ATC GCA GAA GAG-3; pGEX.LT.219–258.BamHI.S,
5-CCTTTAGGATCCGCCTCCTCCCCTGAGCCTCCC
TCG-3; pGEX.LT.1–258.BglII.AS, 5-CCT TTA AGA TCT
TTA ATC TGT AAA CTG AGA TGA CG-3. The BglII
digested 1–258, 79–170, 171–258, and 171–218, and BglII/
BamHI digested 219–258 fragments were cloned into
pGEX4T-2 using a BamHI restriction site. For the GST fusion
LT deletion mutant, GST.dl171–181, GST.dl182–192,
GST.dl193–203, and GST.dl204–218 were generated by the
QuikChange Lighting Site-directed Mutagenesis Kit (Agilent)
using GST.LT(1–258) as a template and the following primer
pairs: dl171–181.S, 5-CCT CCC GAA CAC CAT GAG GAA
GAG ACC ACC AAT TCA GGA AGA-3 and dl171–181.AS,
5-TCTTCCTGAATTGGTGGTCTCTTCCTCATGGTG
TTC GGG AGG-3; dl182–192.S, 5-CCT CTG GAT CCA
GTA GCA GAG AGC CCA ATG GAA CCA GTG TAC CTA
G-3 and dl182–192.AS, 5-CTA GGT ACA CTG GTT CCA
TTGGGCTCTCTGCTACTGGATCCAGAGG-3; dl193–
203.S, 5-CAG GAA GAG AAT CCA GCA CAA GAA CGT
ATG GCA CCT GGG A-3 and dl193–203.AS, 5-TCC CAG
GTG CCA TAC GTT CTT GTG CTG GAT TCT CTT CCT
G-3; dl204–218.S, 5-CCA GTG TAC CTA GAA ATT CTT
CCT CCT CCC CTG AGC CTC CCT CGT C-3 and dl204–
218.AS, 5-GAC GAGGGAGGC TCAGGGGAGGAGGAA
GAA TTT CTA GGT ACA CTG G-3.
MCV LT alanine substitution mutants, GST.LT(1–
258).R204A, T205A, Y206A, G207A, T208A, andW209A were
generated using the QuikChange Lighting Site-directed
Mutagenesis Kit (Agilent) using GST.LT(1–258) as a template
and the following primer pairs: R204A.S, 5-CCT AGA AAT
TCTTCCGCAACGGATGGCACCTGG-3 and R204A.AS,
5-CCA GGT GCC ATC CGT TGC GGA AGA ATT TCT
AGG-3; T205A.S, 5-GAA ATT CTT CCA GAG CGG ATG
GCA CCT GGG-3 and T205A.AS, 5-CCC AGG TGC CAT
CCG CTC TGG AAG AAT TTC-3; Y206A.S, 5-GAA ATT
CTTCCAGAACGGCTGGCACCTGGGAGGATC-3 and
Y206A.AS, 5-GAT CCT CCC AGG TGC CAG CCG TTC
TGG AAG AAT TTC-3; G207A.S, 5-CTT CCA GAA CGG
ATG CCA CCT GGG AGG ATC TC-3 and G207A.AS,
5-GAG ATC CTC CCA GGT GGC ATC CGT TCT GGA
AG-3; T208A.S, 5-CCA GAA CGG ATG GCG CCT GGG
AGG ATC TCT TC-3 and T208A.AS, 5-GAA GAG ATC
CTC CCA GGC GCC ATC CGT TCT GG-3; W209A.S,
5-GAA CGG ATG GCA CCG CGG AGG ATC TCT TCT
GC-3 and W209A.AS, 5-GCA GAA GAG ATC CTC CGC
GGT GCC ATC CGT TC-3. The LT.W209A-V5 mutant was
made by site-directedmutagenesis of pcDNA6.LT-V5 (2) using
PCR primers: W209A.S, 5-GAA CGG ATG GCA CCG CGG
AGG ATC TCT TCT GC-3 and W209A.AS, 5-GCA GAA
GAG ATC CTC CGC GGT GCC ATC CGT TC-3. The Rb
binding domain mutant, gLT.LXCXK-V5 was described previ-
ously (2).
To generate pDsRed.LT, LT-GFPwas used as template using
primers: pDsRed.LT.XhoI.S, 5-CCG CTC GAG ATG GAT
TTA GTC CTA AAT AGG-3 and pDsRed.LT.XmaI.AS,
5-CCC CCC GGG GTT GAG AAA AAG TAC CAG AAT
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C-3. The XhoI/XmaI-digested fragments were cloned into
pDsRed-Monomer-Hyg-N1 (Clontech) using XhoI and XmaI
restriction sites. pDsRed.LT.W209A was made by site-directed
mutagenesis of pDsRed.LT using PCR primers: W209A.S,
5-GAA CGG ATG GCA CCG CGG AGG ATC TCT TCT
GC-3 and W209A.AS, 5-GCA GAA GAG ATC CTC CGC
GGT GCC ATC CGT TC-3.
To generate GST fusions of full-length LT (GST-LT) and LT
hVam6p binding mutant (GST-LT.W209A), pcDNA6.LT-V5
(2) and pcDNA6.LT.W209A-V5 (described above) were
digested with EcoRV and XhoI. These fragments were cloned
into pALEX vector, which was first digested with NotI, sub-
sequently treated with mung bean exonuclease, and further
digested with XhoI. To generate maltose-binding protein-
tagged hVam6p (MBP-hVam6p), hVam6p was amplified
using 5-CG GGA TCC CAC GAC GCT TTC GAG CC-3
and 5-GC TCT AGA TCA AGT GTC AGC TGG GTT
TAC-3 primer pairs. The BamHI- and XbaI-digested PCR
product was then inserted into the corresponding restriction
sites of the pMAL-2c vector (New England BioLabs).
pXS-HA-hVam6p and pXS-Myc-hVam6p were kindly pro-
vided by Dr. Juan S. Bonifacino (15). mVps39.FL-GFP,
mVps39.Nter-GFP, mVps39.Cter-GFP, and mVps39.CNH-
GFP constructs were kindly provided by Dr. J. Paul Luzio (20).
To generate mVps39.(CNHCLH)-GFP, mVps39.FL-GFP
was used as template using primers: pEGFP.mVps39.dl.KpnI.S,
5-CGG GGT ACC GTG CTG AGA GAC TTC-3 and
pEGFP.mVps39.dl.BamHI.AS, 5-CGC GGA TCC TCA GGT
GTC GGC TGA-3. The KpnI/BamHI-digested fragment was
cloned into pEGFP-C1 (Clontech).
Cell Culture andTransfection—U2OS (ATCC), 293 (ATCC),
293H (Invitrogen), 293FT (Invitrogen), HT1080 (ATCC), and
HeLa (ATCC) cells were maintained in DMEM (Mediatech)
supplemented with 10% fetal bovine serum (FBS) at 37 °C in a
5%CO2 incubator. Cells in 100-mmor 12-well plates (60% con-
fluence) were transfected 24 h after plating with 6 or 2 g of
plasmid DNA using FuGENE-6 (Roche Applied Science) fol-
lowing the manufacturer’s instructions. UISO (2), MCC13 (2),
MCC26 (2), MKL-1 (2), MS-1 (21), andWaGa (21) were grown
in RPMI 1640 (Sigma) supplemented with 10% FBS.
Tandem Affinity Purification (TAP)—293H cells transfected
with pNTAP.SV40.T1–136, pNTAP.MCV.T4, and pNTAP.
MCV.T5 were resuspended in lysis buffer containing protease
inhibitor mixture (Roche Applied Science) and 0.1 mM PMSF.
Cells were subjected to three successive rounds of freeze-thaw
by incubating on dry ice for 10 min then in cold water for 10
min. Supernatant was collected after centrifugation at 16,000
g for 10min. 0.5M EDTA and 14.4M -mercaptoethanol (Strat-
agene InterPlayMammalianTAPSystem)were added.Washed
streptavidin resin (50% slurry) was added to the lysate, followed
by rotation at 4 °C for 2 h to allow tagged proteins to bind. Resin
was collected by centrifugation at 1,500  g for 5 min and
washed twice in 1 ml of streptavidin binding buffer. Streptavi-
din elution bufferwas added to the resin, followed by rotation at
4 °C for 30 min to elute protein complexes. The resin was cen-
trifuged at 1,500  g for 5 min and the supernatant was trans-
ferred to a fresh tube. Streptavidin supernatant supplement,
calmodulin binding buffer, and the washed calmodulin resin
(50% slurry) were added to the supernatant, followed by rota-
tion at 4 °C for 2 h to allow protein complexes to bind to the
calmodulin resin. Then the resin was washed twice in calmod-
ulin binding buffer and collected by centrifugation at 1,500  g
for 5 min. Calmodulin elution buffer was added to the calmod-
ulin resin and rotated at 4 °C for 30 min to elute protein com-
plexes. Supernatant containing purified protein complexes was
collected after centrifugation.
Mass Spectrometric Analysis—Individual protein bands were
excised from polyacrylamide gels and washed twice with 50%
acetonitrile in HPLC grade water and sent to the Mass Spec-
trometry Core Facility at Beth Israel Deaconess Medical Cen-
ter, Boston, MA, for characterization.
Antibodies—Anti-MCV LT antibody CM2B4 was generated
as previously described (22). hVam6p rabbit polyclonal anti-
body was kindly provided by Dr. Robert C. Piper (23). Anti-V5
rabbit antibody (Bethyl Laboratories), anti-HA.11 clone 16B12
monoclonal antibody (Covance), rabbit polyclonal recognizing
GFP (Abcam), anti-Myc tag clone 4A6 antibody (Millipore),
purified mouse anti-human retinoblastoma protein antibody
(BD Pharmingen), anti-human CD107a (LAMP1) Alexa Fluor
488 (eBioscience), phospho-4EBP-1Thr-37/46 (Cell Signaling),
phospho-4EBP-1 Ser-65 (Cell Signaling), anti-mouse second-
ary antibody (GE Healthcare), and anti-rabbit secondary anti-
body (Sigma) were purchased commercially. hVam6p/Vps39
antibodies tested include rabbit polyclonal catalog number
16219-1-AP (Proteintech), goat polyclonals sc-104759 and
sc-104761 (Santa Cruz), mouse polyclonal ab69669 (Abcam),
and rabbit polyclonal ab90516 (Abcam).
Immunoprecipitation—U2OS cells were co-transfected with
pXS-HA-hVam6p and either pcDNA6/V5-HisB plasmid
(Invitrogen) or LT plasmid (pcDNA6.gLT-V5, cLT-V5,
cLT339-V5, cLT350-V5) using FuGENE-6 (Invitrogen). Cells
were harvested 48 h after transfection suspended in lysis buffer
(50 mM Tris-HCl, 0.15 M NaCl, 1.5% Nonidet P-40, pH 7.4)
supplemented with protease inhibitors. Precleared lysates were
immunoprecipitatedwith rabbit anti-V5 (Bethyl) for 2 h at 4 °C.
Lysates were incubated with Protein A/G-Sepharose beads
(Santa Cruz) for 1 h at 4 °C, collected, and washed with lysis
buffer. Beads were resuspended in 3  SDS loading buffer and
proteins were separated by SDS-PAGE. Immunoblotting was
performed with anti-HA (Covance).
Immunoblot Analysis—Transfected cells were lysed in buffer
(40mMTris-HCl, pH 7.4, 120mMNaCl, 0.5%Triton, 0.3% SDS)
containing protease inhibitormixture (RocheApplied Science).
Sonicated lysates were electrophoresed in 10% SDS-PAGE,
transferred to nitrocellulose membrane (GE Healthcare), and
reacted with anti-HA (1:1,000 dilution, Covance) overnight at
4 °C, followed by anti-mouse IgG-HRP conjugates (1:3,000
dilution, GE Healthcare) for 1 h at room temperature. Detec-
tion of peroxidase activity was performed by Western Light-
ning Plus-ECL reagent (PerkinElmer Life Sciences).
Immunofluorescence Analyses—For high resolution micros-
copy, cells were fixed with 4% paraformaldehyde for 20 min,
permeablized with phosphate-buffered saline (PBS) with 0.2%
Triton X-100, blocked with 10% BSA, and then incubated with
anti-Myc (1:100 dilution, Millipore) overnight at 4 °C. Second-
ary antibody (Alexa Fluor 568-conjugated anti-mouse or Alexa
Nuclear Translocation of hVam6p by MCV Large T Antigen
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Fluor 488-conjugated anti-mouse, 1:1,000 dilution, Invitrogen)
was incubated for 1 h at room temperature. All antisera were
diluted in 1%BSA in PBS, and interveningwashes of slides were
carried out three times with PBS for 15 min. For the LAMP1
clustering experiment, transfected HeLa cells were fixed and
permeabilized in PBS with 10% FCS, 2% paraformaldehyde,
0.3% saponin for 15 min at room temperature as previously
described (24). Cells were washed twice in PBS with 0.03% sap-
onin before and after staining with anti-human CD107a
(LAMP1) Alexa Fluor 488 (eBioscience). Cells were counter-
stained with 4,6-diamidino-2-phenylindole (DAPI) and ex-
amined under a fluorescence microscope (AX70, Olympus).
Confocal Microscopy—MKL-1 cells were fixed with 4% para-
formaldehyde for 20 min at 4 °C, permeablized with PBS with
0.2% Triton X-100, blocked with 10% BSA, incubated with rab-
bit polyclonal anti-hVam6p (1:100 dilution, fromDr. Robert C.
Piper (23)) for 4 h at room temperature, followed by incubation
withmouse anti-LaminB1 (1:50 dilution, ZYMED) overnight at
4 °C. Secondary antibody (Alexa Fluor 488-conjugated anti-
mouse and Alexa Fluor 568-conjugated anti-rabbit, 1:1,000
dilution, Invitrogen) was applied for 1 h at room temperature.
Cells were stained with DRAQ5 (1:1,000 in PBS, Biostatus) for
10 min at room temperature, washed in PBS for 10 min, and
mounted with VECTASHIELD mounting medium for fluores-
cence (Vector Laboratories, Inc.). Confocal images were
acquired using a Leica TCSSL confocal microscope.
Glutathione S-Transferase (GST) Fusion Purification and
GST Pull-down Assay—Cultures of JM109 bacterial host cells
expressing GST fusion plasmids were grown overnight, fol-
lowed by subculture (1:10) into 250 ml of LB with ampicillin.
After 1 h, isopropyl -D-1-thiogalactopyranoside was added at
0.5 mM final concentration. Induced cultures were grown for
another 3–4 h and harvested by centrifugation at 3,000  g for
10 min. Cell pellets were resuspended in cold NETN (0.5%
Nonidet P-40, 1 mM EDTA, 50 mM Tris, pH 8.0, 120 mMNaCl)
containing protease inhibitors, followed by sonication. Super-
natants were collected by centrifugation and 300 l of glutathi-
one-Sepharose 4B beads (GSH beads, 50% slurry in NETN)
were added followed by incubation at 4 °C for 30 min. GSH
beads were washed 5 times with NETN buffer. For the binding
assay, 293FT cells were transiently transfected with HA-
hVam6p and harvested 48 h after transfection in NETN lysis
buffer in the presence of protease inhibitors. Lysates were pre-
cleared using 20l of GSHbeads loadedwithGST (pGEX4T-2)
for 1 h at 4 °C. Complexes were collected by addition of 30l of
GSH beads loaded with appropriate fusion protein, rotation
was for 2 h at 4 °C followed by centrifugation. The isolated
beads were washed three times for 30 min at 4 °C with NETN
and eluted with 50 l of freshly made elution buffer (25 mM
glutathione, 50 mM Tris-HCl, pH 8.8, 200 mM NaCl, pH 8.8).
Elution samples were resuspended in 3 SDS loading buffer
FIGURE 1. Identification of hVam6p as an MCV LT interactor. A, schematic diagram of MCV LT showing the site of the MUR and location of T4 and T5 LTs fused
to N-terminal dual tags and used for TAP experiments. Positions of tumor-derived T antigen truncations cLT350 and cLT339 are shown (arrows). NLS, nuclear
localization signal (30); CBP, calmodulin-binding protein; SBP, streptavidin-binding protein. B, silver stain of SDS-PAGE gel separating protein lysates after TAP
isolation. Arrows indicate various TAP-tagged LT proteins stably expressed in 293H cell lines. A 120-kDa band, present only in MCV LT TAP from T4 and T5, was
excised for mass spectrometric analysis. hVam6p peptide sequences identified from these bands are shown. C, lysates from U2OS cells transiently overex-
pressing HA-hVam6p and V5-tagged LTs were immunoprecipitated for LT with anti-V5 antibody and immunoblotted for hVam6p using anti-HA antibody.
D, endogenous LT-hVam6p interaction in MCV-negative and MCV-positive cell lines. MCV LT is detected only in MCV-positive cell lines (MKL-1, MS-1, and WaGa)
and LT immunoprecipitation pulls down endogenous hVam6p protein.
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and proteins were separated by SDS-PAGE using 10% poly-
acrylamide gels. Immunoblotting was performed with anti-HA
(Covance).
MBP Fusion Purification and MBP Pull-down Assay—GST-
LT, GST-LT.W209A, and MBP-hVam6p were expressed in
Escherichia coliRosetta (DE3) pLysS and BLR(DE3) (Novagen),
respectively, and induced with 0.5 mM isopropyl -D-1-thioga-
lactopyranoside for 2 h at 37 °C. Cells were harvested by centri-
fugation at 6,000  g for 15 min at 4 °C. GST fusion proteins
were extracted in lysis buffer (0.5%Nonidet P-40, 250mMNaCl,
50 mM Hepes/KOH, pH 7.6, 1 mM EDTA, pH 7.4) supple-
mentedwith 0.2mg/ml of lysozyme andprotease inhibitormix-
ture (Roche Applied Science). MBP-hVam6p was extracted in
ice-cold column buffer (200mMNaCl, 20mMTris-HCl, pH 7.4,
1 mM EDTA, 0.02% NaN3) supplemented with 0.2 mg/ml of
lysozyme, 1 mM DTT, and 1 mM PMSF. The suspensions were
incubated for 20 min on ice. Following repeated freeze-thaw
cycles, cells were sonicated on ice and centrifuged at 10,000 g
for 30 min at 4 °C. For purification of fusion proteins, cleared
supernatants were incubated with 1/100th volume of equili-
brated glutathione-Sepharose 4B beads (GE Healthcare) or
amylose resin (New England Biolabs) for 30 min at room tem-
perature or 2 h at 4 °C, respectively. Beads were collected by
centrifugation at 1,000  g for 1 min and washed four times
with lysis buffer. Fusion proteins were eluted by addition of 10
mM reduced glutathione, 50 mM Tris-HCl, pH 8.0, or 30 mM
maltose, 50 mM Tris-HCl, pH 8.0, followed by silver staining
analysis.
For the pull-down experiment, MBP-hVam6p-bound amy-
lose resin beads were incubated with eluted GST, GST-LT, or
GST-LT.W209A proteins for 2 h at 4 °C in binding buffer (0.5%
Nonidet P-40, 120 mM NaCl, 50 mM Tris, pH 8.0, and 1 mM
EDTA) supplemented with protease inhibitor mixture (Roche
Applied Science). Beads were washed three times with binding
buffer for 30 min at 4 °C, resuspended in SDS loading buffer,
boiled for 10 min, and proteins were separated on a 8% SDS-
PAGE gel. Immunoblotting was performed with anti-MCV LT
antibody CM2B4 (22) and anti-MBP (New England Biolabs).
TGF--inducible Luciferase Reporter Assays—HT1080 cells
were transfected with the TGF--inducible reporter p3TP-Lux
(Addgene) and empty vector, wild-type LT, hVam6p binding
mutant LT, alone or together with hVam6p. The p3TP-Lux
reporter contains three 12-O-tetradecanoylphorbol 13-acetate
response elements from the human collagenase promoter and
the TGF- responsive element from the plasminogen activator
inhibitor-1 promoter ligated upstream to the adenovirus E4
minimal promoter (25). 24 h after transfection, cells were
replaced with fresh DMEM with 0.2% FBS, left non-treated or
treated with recombinant human TGF-1 (Invitrogen) at 5
ng/ml for 18 h. Transfection efficiency was normalized with
pRL-null vector (Promega). Renilla and firefly luminescence
activities were measured using the Dual Luciferase Reporter
Assay System (Promega) on amicroplate luminescence counter
(TopCount-NXTTM, Packard).
RESULTS
MCV Large T Antigen Associates with hVam6p—To identify
novel cellular proteins associated withMCV LT, we performed
FIGURE 2. Localization of hVam6p. A, nuclear relocalization of hVam6p in
U2OS cells during MCV LT expression. U2OS cells were transfected with Myc-
hVam6p alone (a– d) or together with EGFP-LT (e– h), EGFP-cLT339 (i–l), EGFP-
cLT350 (m–p), and EGFP-SV40.LT (q–t). The expression of hVam6p is visualized
with anti-Myc antibody and Alexa Fluor 568-conjugated anti-mouse (TRITC),
whereas the LTs are visualized by tagged EGFP fluorescence. hVam6p is pres-
ent in the cytoplasm (d), but relocalized to the nucleus with wild-type LT
expression (h). In a representative view of four cells (1– 4), 1 and 2 contain both
overexpressed wild type, full-length LT and hVam6p; whereas, cells 3 and 4
show only overexpressed hVam6p. hVam6p relocalizes to the nucleus only
when LT is also present. Tumor-derived, truncated MCV LT protein (cLT339)
also relocalize hVam6p (l), however, a tumor-derived MCV LT lacking a nuclear
localization signal (cLT350) fails to relocalize hVam6p to the nucleus (p). No
hVam6p relocalization is seen in conjunction with SV40 LT protein expression
(t). B, immunofluorescence detection of endogenous hVam6p in naturally
infected, MCV positive MKL-1 (a– d) and MS-1 (e– h) cell lines. Two patterns are
seen. A portion of endogenous hVam6p shows an intranuclear localization
similar to MCV LT (solid arrow), another portion demonstrates prominent peri-
nuclear localization (dashed arrow) distinct from LT. In MCV negative UISO cell
lines (i–l), no LT is expressed and hVam6p remains cytoplasmic (arrowhead).
C, confocal microscopy of LT expressing MKL-1 cells shows hVamp6p (c) dis-
tributed largely in the same pattern as Lamin B1 (b), a marker for the nuclear
membrane. In addition, hVam6p is also present in a diffuse pattern within the
nuclear compartment (c). In panel e showing another typical cell, analyzed
with cross-sectional graphing fluorescence intensity from DNA (blue), Lamin
B1 (green), and hVamp6 (red) show increased hVam6p signal within the
nuclear compartment defined by DNA and demarcated by Lamin B1.
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TAP using two LT MUR fragments fused with N-terminal cal-
modulin-binding protein and streptavidin-binding protein tags
(Fig. 1A). After stably expressing the dual-tag constructs in
293H cells, LT MUR interacting proteins were separated on
SDS-PAGE gel. EGFP and SV40 T1–136 expressing controls
were used to identify unique proteins only present in MCV LT
samples. Following silver staining, a specific band at 120 kDa
(Fig. 1B) was isolated and identified by mass spectrometry as
hVam6p (hVps39). Rb was also recovered from this fraction,
consistent with our previous report (2).
To confirm LT-hVam6p interaction, we performed a co-im-
munoprecipitation assay using U2OS cells overexpressing
HA-hVam6p together with V5-tagged genomic LT (also
expressing small T and 57 KT proteins), cDNA LT (cLT,
expressing LT alone), or two tumor-derived LT (cLT339 and
cLT350) proteins (Fig. 1C). All forms of MCV LT co-immuno-
precipitated hVam6p, whereas no specific immunoprecipita-
tion was found with the empty vector. To investigate endoge-
nous interaction between hVam6p and MCV LT, the LT
protein was immunoprecipitated using anti-MCV LT antibody
CM2B4 (22). MCC cell lines harboring MCV (MKL-1, MS-1,
and WaGa) were compared with MCV negative cell lines
(UISO, MCC13, and MCC26). Immunoprecipitated proteins
were immunoblotted with anti-hVam6p antibody (Fig. 1D).
Robust immunoprecipitation was detected in MKL-1 and
WaGa, and to a lesser extent in MS-1 cells but not in MCV-
negative cell lines. These results indicate that hVam6p is an
authentic binding partner for LT in vivo. Interaction between
hVam6p, a cytoplasmic protein, and MCV LT, a nuclear pro-
tein is unexpected.
Co-localization of MCV LT and hVam6p—To determine
that the interaction occurs in cells, we performed immunoflu-
orescence localization of MCV LT and hVam6p. LT-EGFP
fusion proteins and Myc-hVam6p were transiently overex-
pressed in U2OS cells followed by anti-Myc immunostaining.
Immunofluorescence reveals that in the absence of MCV LT,
hVam6p is distributed in the cytoplasm (Fig. 2A, a–d) as pre-
viously noted (15, 24). However, in the presence of MCV LT or
cLT339, which both harbor nuclear localization signals,
hVam6p translocates to the nucleus and co-localizes with LT
(Fig. 2A, e–h and i–l). The naturally occurring tumor MCV
cLT350 lacking an nuclear localization signals, however, co-lo-
calizes with hVam6p in the cytoplasm (Fig. 2A,m–p). SV40 LT
does not co-localize or mislocalize hVam6p to the nucleus (Fig.
2A, q–t), consistent with hVam6p being an interactor specific
for theMCVLT.We also examined endogenous hVam6p local-
ization in MCV-positive MCC cell lines (MKL-1 and MS-1).
Immunofluorescence shows that a portion of hVam6p is pres-
ent in the nucleus (Fig. 2B, c and g, solid arrow). Additionally, in
naturally infected MCV T antigen expressing Merkel cell car-
cinoma-derived cell lines, hVam6p also displays a perinuclear
dot-like localization in a subpopulation of tumor cells (Fig. 2B,
c, dashed arrow). In comparison, hVam6p is not relocalized to
the nucleus in anMCVnegative cell line, UISO (Fig. 2B, i–l). To
confirm this, we performed confocal microscopy, which
showed similar results as conventional fluorescence micros-
copy. hVam6p is present in the nucleus, colocalizes with Lamin
B1 to the nuclear membrane, and focally in a perinuclear pat-
tern. Analysis of single cell fluorescence profiles along two-di-
mensional axis shows intranuclear, nuclear membrane, as well
as a perinuclear concentration of signal for hVam6p (Fig. 2C).
Fine Mapping of the MCV LT Domain Interacting with
hVam6p—To better characterize the association of MCV LT
and hVam6p, wemapped the domain ofMCV LT necessary for
its associationwith hVam6p.Using a series of LTMURdeletion
FIGURE 3. Mapping the hVam6p binding site on MCV LT antigen. A, dia-
gram of GST-tagged LT deletion constructs. GST-LT fusion proteins were incu-
bated with protein extracts of 293FT cells transfected with HA-hVam6p.
Bound proteins were revealed by immunoblotting with anti-HA antibody (top
panel). The GST fusion LT proteins were visualized by Ponceau S staining
(bottom panel). B, further deletion analysis of the 171–218 subregion in the
context of 1–258 LT. Ponceau S shows comparable expression of LT con-
structs and 1–258 has appropriately retarded migration (bottom panel). Co-
immunoprecipitation shows that only dl204 –218 loses the ability to interact
with hVam6p (top panel). C, schematic diagram of MCV LT alanine substitu-
tion mutants based on localization of hVam6p binding to residues 204 –218
(A and B). LFCDE, Rb-binding domain.
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mutants (1–258, 79–170, 171–258, 171–218, and 219–258)
fused to GST (Fig. 3A), we performed GST pulldowns on
extracts from 293FT cells overexpressing hVam6p and found
171–218 to be the minimal fragment that binds hVam6p (Fig.
3A). Further mapping was performed using LT deletions cre-
ated from this minimal region (dl171–181, dl182–192, dl193–
203, and dl204–218); only the dl204–218 mutant was found to
be defective in binding hVam6p (Fig. 3B). Six adjacent amino
acid alanine substitution mutations (R204A, T205A, Y206A,
G207A, T208A, and W209A) were then generated in the
dl204–218 region (Fig. 3C, top panel). Trp-209 is positioned 2
residues N-terminal to the LXCXE domain andwas found to be
essential for hVam6p binding (Fig. 3C, bottom panel). This was
confirmed by engineering the W209A substitution into full-
length V5-tagged LT and performing immunoprecipitation in
U2OScellswithHA-taggedhVam6p (Fig. 4A). The alanine sub-
stitution at LT Trp-209 completely abolishes LT interaction
with hVam6p. When this alanine substitution is cloned into an
EGFP-tagged LT (LT.W209A-EGFP), co-localization and
nuclear translocation of hVam6p are lost (Fig. 4B).
To test if LT-hVam6p association is direct, we produced
maltose-binding protein-tagged hVam6p (MBP-hVam6p),
GST-LT, and GST-LT.W209A in bacteria, followed by a MBP
pull-down assay. As shown in Fig. 5A, MBP-hVam6p specifi-
cally pulled down GST-LT, but not GST alone or the GST-
LT.W209A mutant, indicating a direct binding of MCV LT to
hVam6p. As shown in the input lanes, similar amounts of wild-
typeMCV LT and the mutant were used. Reprobing of the blot
with MBP antibody revealed equivalent loading of MBP-
hVam6p for all of the pull-downs (Fig. 5B).
Because Trp-209 is adjacent to the LXCXERb-bindingmotif,
we tested whether a previously described mutation in the Rb
binding motif (2) also affects hVam6p interaction with MCV
LT. As seen in Fig. 6, substitution of lysine for glutamate at
position 216 (LT.LXCXK), disrupts Rb interactions with LT
(Fig. 6A) but has no effect on the hVam6p interaction with LT
(Fig. 6B). Additionally, we tested the LT-hVam6p binding
defective mutant LT.W209A and found it retains interaction
with Rb (Fig. 6C). These findings suggest that Rb and hVam6p
interaction domains are discrete sites. Because these two inter-
action sites are in close proximity, we next sought to determine
whether hVam6p associates with Rb in the absence or presence
of LT. As seen in Fig. 6D, hVam6p neither interacts with Rb
directly, nor is bridged by LT to Rb. Similar results are found for
the Rb family members, p107 and p130 (data not shown).
FIGURE 4. MCV LT.W209A mutant is defective in interacting with and
relocalizing hVam6p. A, mutation at Trp-209 on full-length LT completely
abolished LT-hVam6p binding. Lysates from U2OS cells transiently co-ex-
pressing HA-hVam6p with empty vector, LT-V5, or LT.W209A-V5 were immu-
noprecipitated (IP) for LT with anti-V5 antibody and immunoblotted (IB) for
hVam6p by anti-HA antibody. B, LT.W209A fails to relocalize hVam6p to the
nucleus. U2OS cells were co-transfected with Myc-hVam6p and LT-DsRed or
LT.W209A-DsRed. hVam6p is visualized with anti-Myc antibody and Alexa
Fluor 488-conjugated anti-mouse antibody (FITC), whereas the wild-type and
mutant LTs are visualized by DsRed fluorescence.
FIGURE 5. Direct binding of MCV LT to hVam6p. MBP-hVam6p-bound amy-
lose resin beads were incubated with eluted GST, GST-LT.W209A, or GST-LT
proteins for a pull-down assay. 5% input and bound proteins were separated
on an 8% SDS-PAGE gel. Immunoblotting (IB) was performed with anti-MCV
LT CM2B4 antibody (A) and anti-MBP antibody (B).
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Vam6p CLH Repeat Domain Is Responsible for Binding to
MCV LT—hVam6p has a NH2-terminal CNH domain and a
central CLH repeat domain, both of which are required for
lysosome clustering and fusion (15). We used a series of EGFP-
tagged murine Vps39 (mVps39/mVam6p is near identical to
hVps39/hVam6p) deletions (20) to map the LT binding site on
mVps39 (Fig. 7A). U2OS cells were transfected with LT and
mVps39 deletion mutants, followed by LT immunoprecipita-
tion and immunoblotting for EGFP-mVps39. As seen in Fig. 7B,
full-length mVps39 and mVps39 having the centrally located
CLH domain and either N-terminal or C-terminal deletions all
strongly interact with LT. In contrast, constructs lacking the
CLH domain (CNH and (CNHCLH)) fail to interact with
LT suggesting that the Vam6p CLH domain is critical in bind-
ing LT.
Functional Interactions of MCV LT with hVam6p: Lack of
Effect on TGF- and mTOR Signaling—Because hVam6p has
been reported to be identical with the TRAP-1-like protein
except for an 11-amino acid insertion and TRAP-1-like protein
functions to balance Smad2 and Smad3 signaling (17), we
examined the MCV LT effect on TGF- signaling in HT1080
cells using the TGF--responsive luciferase reporter 3TP-Lux.
Without TGF- treatment, hVam6p expression has a minimal
effect on basal 3TP-Lux activity but reporter activity nearly
FIGURE 6. Rb and hVam6p interaction domains are discrete sites on LT. A, the LT.LXCXK mutant fails to bind Rb. U2OS cell lysates co-expressing HA-Rb
with empty vector, LT, or Rb-binding mutant LT.LXCXK were immunoprecipitated for LT by anti-V5 antibody and immunoblotted for HA-Rb. B, LT.LXCXK
mutant retains hVam6p interaction. U2OS cell lysates co-expressing HA-hVam6p with empty vector, LT, or Rb-binding mutant LT.LXCXK were immu-
noprecipitated for LT by anti-V5 antibody and immunoblotted for HA-hVam6p. C, LT.W209A mutant has no effect on Rb binding. U2OS cell lysates
co-transfected with empty vector, LT, or LT.W209A were immunoprecipitated for LT by anti-V5 antibody and immunoblotted for HA-Rb. D, hVam6p does
not associate with Rb in the presence or absence of LT. Left panel, 5% lysate input for LT, hVam6p, and Rb. Right panel, immunoprecipitation (IP) and
immunoblotting (IB) for Rb.
Nuclear Translocation of hVam6p by MCV Large T Antigen
17086 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 286 • NUMBER 19 • MAY 13, 2011
 by guest, on Novem
ber 26, 2012
w
w
w
.jbc.org
D
ow
nloaded from
 
doubles with hVam6p expression after TGF- treatment (Fig.
8A). LT expressionmodestly reduces this activity but this effect
is independent of the LT.W209A substitution, suggesting that
LT does not directly target TGF- signaling through hVam6p
(Fig. 8A).
Vam6p (Vps39 in yeast) also functions as a Rag family
GTPase nucleotide exchange factor to promote TORC1 activa-
tion in response to increased amino acid concentrations in the
environment of yeast, leading to mTOR-dependent phosphor-
ylation of the cap-binding protein 4EBP-1 (26). To assess the
effect of LT on mTOR signaling, we transfected 293 cells with
HA-hVam6p together with wild-type LT or LT.W209A, alone
or together with hVam6p. After overnight serum starvation
and 2 h amino acid starvation, 4EBP-1 phosphorylation was
assessed byWestern blotting. Phospho-4EBP-1 Thr-37/46 and
Ser-65 levels are low under starvation conditions compared
with cells grownwith serumand amino acids (baseline, Fig. 8B).
hVam6p had no obvious activity on 4EBP-1 phosphorylation
either during starvation or under replenished conditions. Fur-
thermore, no significant or consistent change in 4EBP-1 phos-
phorylation was noted after expression of either the wild-type
LT or LT.W209A (Fig. 8B).
MCVLTDisrupts hVam6p-induced Lysosome Clustering—A
third function described for hVam6p overexpression is promo-
tion of lysosome clustering (15, 24). HeLa cells were transiently
transfected with LT or the hVam6p binding mutant, alone
or together with Myc-hVam6p, and lysosome clustering was
assessed by cytoplasmic clustering of lysosomal-associated
membrane protein 1 (LAMP1). In the absence of hVam6p over-
expression, there is no obvious difference between an empty
vector, LT, and the mutant on LAMP1 staining (data not
shown). Under standard growth conditions, LAMP1 shows a
diffusely punctate distribution in the cytoplasm (Fig. 9, a–d).
Overexpression of hVam6p induces perinuclear lysosome clus-
tering as previously reported (15, 24) (Fig. 9, e–h). This cluster-
ing is abolished by expression of wild-type LT (Fig. 9, i–l) but
not LT.W209A (Fig. 9, m–p). To determine whether nuclear
sequestration of hVam6p is required for inhibition of lysosomal
clustering, hVam6pwas co-expressed withMCV350 LT, which
lacks a nuclear localization signal but still interacts with
FIGURE 7. Mapping of the LT binding site on Vam6p to regions containing
the central clathrin homology repeat domain. A, schematic representation
of murine Vps39 (mVps39) and various deletion constructs. B, immunopre-
cipitation (IP) in U2OS cells of mVps39 deletions with MCV LT, using LT mutant
as negative control (last lane). Top panel, immunoprecipitation (IP) of LT with
CM2B4 antibody and immunoblotting (IB) of mVps39 with anti-EGFP anti-
body. Middle panel, 5% lysate input of each deletion construct. Bottom panel,
5% lysate input of LT or LT mutant.
FIGURE 8. Lack of effect on TGF- and mTOR signaling. A, LT-hVam6p bind-
ing has no significant effect on the TGF- pathway. HT1080 cells were trans-
fected with TGF- inducible reporter p3TP-Lux and empty vector, wild-type
LT, hVam6p binding mutant LT, alone or together with hVam6p. 24 h after
transfection, cells were replaced with fresh DMEM with 0.2% FBS, left non-
treated or stimulated with recombinant human TGF-1 at 5 ng/ml for 18 h.
Reporter activities were measured using the Dual Luciferase Reporter Assay
System (Promega) and normalized to non-treated empty vector-transfected
conditions. Independent experiments were performed in triplicate three
times. Error bars and p values are shown. B, LT-hVam6p binding has no effect
on the mTOR pathway. 293 cells were transfected with empty vector, wild-
type LT, hVam6p binding LT mutant, alone or together with hVam6p, left in
serum starvation (0.3% FBS) overnight. On the second day cells were
starved in amino acid-free medium for 2 h and replenished with amino
acid solution for 1 h. Non-stimulated and stimulated lysates were sub-
jected to a Western blot analysis to probe for mTOR downstream of the
target 4EBP-1 phosphorylation.
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hVam6p (Fig. 2). Clustering was present with MCV350 LT
expression (Fig. 9, q–t) suggesting that LT binding alone to
hVam6p is insufficient to antagonize hVam6p-induced lyso-
somal clustering andnuclear sequestration is required to antag-
onize this effect.
DISCUSSION
We identified cytoplasmic human Vam6p as a unique inter-
actor for nuclear MCV LT. The hVam6p interaction domain is
not present in SV40 LT and we find that direct targeting of
hVam6p does not occur with SV40 LT. To our knowledge,
hVam6p has not been reported as a binding partner for any
other viral protein. MCV LT associates with endogenous
hVam6p in MCV positive cell lines making it likely that this
interaction has physiological consequences. Interestingly, LT
relocalizes hVam6p from the cytoplasm to the nucleus. Nuclear
sequestration of a cytoplasmic protein is an unusual regulatory
phenomenon that has been described for cytomegalovirus
TRS-1 protein sequestration of protein kinase R (27), poliovi-
rus-induced nuclear relocalization of eIF4E through eIF4G
cleavage (28), and HPV-induced nuclear relocalization of p80
by the E1 protein (29). Although the MCV T antigen causes a
loss-of-function for hVam6p involvement in lysosomal traffick-
ing, we donot know if there is a subsequent gain-of-function via
nuclear relocalization of hVam6p.
Current evidence indicates that MCV is a bona fide human
cancer virus causing most cases of Merkel cell carcinoma (21).
Like other human polyomaviruses, MCV is a common if not
ubiquitous infection that does not normally integrate into the
host chromosome as part of its life cycle. Virus mutation leads
to genomic integration that contributes to tumor formation (1,
2). Integrated MCV genomes are clonal within tumors and
most tumor cells express abundant LT protein (22). Expression
of the full-length LT protein in cells harboring an integrated
MCV genome, however, will lead to unlicensed replication
from the integrated viral origin that is predicted to cause DNA
fragmentation (2). Thus, additional virus mutations truncating
the LT to eliminate its DNA replication capacity are commonly
found in tumor-derived viruses. MCV species found in tumors
are replication defective and do not represent free-living and
transmissible viruses.
Our studies suggest the possibility that hVam6p sequestra-
tion might play a role in MCV replication rather than tumori-
genesis. Unlike most MCV LT proteins, the tumor-derived
MCV350 strain LT protein possesses a truncation that elimi-
nates its nuclear localization signal (30). Most MCV LTs are
localized to the nucleus, whereas MCV350 LT has a diffuse
nuclear and cytoplasmic distribution. Although MCV350 LT
still interacts with hVam6p, it does not inhibit lysosomal clus-
tering. This circumstantial evidence suggests that this hVam6p
antagonism by MCV LT involves nuclear sequestration rather
than simple binding, and that this sequestration may not be
critical to MCV-induced tumorigenesis. In a limited survey of
TGF- and mTOR signaling functions, we did not observe an
effect for LT dependent on hVam6p interaction. We cannot
FIGURE 9. LT inhibits hVam6p-induced lysosome clustering in HeLa cells. HeLa cells were transfected with Myc-hVam6p alone (e– h), together with LT (i–l),
LT.W209A (m–p), or cLT350 (q–t). The expression of hVam6p was visualized with anti-Myc antibody and Alexa Fluor 568-conjugated anti-mouse antibody
(TRITC). LAMP1 was visualized with anti-human CD107a (LAMP1) Alexa Fluor 488. hVam6p-induced clustering of lysosomes (h) is lost when full-length LT (l) but
not LT.W209A (p) or cLT350 (t) is co-expressed.
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rule out the possibility thatmore extensive studiesmight reveal
contributions to cell growth and proliferation by MCV LT tar-
geting of hVam6p. In fact, interference with hVam6p function
was found to enhance growth factor independent cell survival
and potentially modulate autophagy (24, 31).
At present, there is no MCV replication system available to
test for specific functions of LT in virus assembly, transmission,
and replication butwe anticipate that these questions can even-
tually be addressed using MCV molecular clone viruses.
Because MCV is only found in high copy number in tumors,
naturally occurring replication-competentMCVgenomes have
not been cloned until recently (32, 33).
Clues to the functions for MCV LT binding to hVam6p may
come from infection studies of other polyomaviruses. Polyoma-
viruses make use of endosomal and lysosomal trafficking to
transit from the cell membrane to the nucleus, although precise
mechanisms differ between polyomaviruses (34). Murine
polyomavirus, for example, binds the ganglioside GD1a and is
transported to endolysosomes where pH-dependent confor-
mational changes allow transport of the virus into the endoplas-
mic reticulum and then the nucleus for uncoating and replica-
tion (35). SV40 transit to the endoplasmic reticulum is
dependent on viral coat protein binding initially to caveosomes
and subsequently to caveolin-free membrane structures (36).
Little is known about the cellular functions of hVam6p in lyso-
somal trafficking and many of its functions are inferred from
studies of the yeast homolog, Vps39 (37). Disruption of Vps39
interaction with the C-Vps complex mislocalizes Vps39 from
membrane-enriched subcellular fractions to the cytosolic frac-
tion and causes hydrolase missorting defects, suggesting that
localization of Vps39 to the vacuole is essential for vacuolar
protein transport (38).Nuclear sequestration of hVam6p canbe
expected to affect its regulatory interactions with the C-Vps
complex in human cells but it is unlikely to completely disrupt
this complex. A class C-Vps component, hVps11, is not mislo-
calized by MCV LT protein expression (data not shown).
Because LT is an early viral protein, it is more likely that target-
ing of hVam6p plays an important role in viral egress rather
than entry.
Although we cannot completely exclude that some of the
Piper hVam6p antibody reactivity could be nonspecific, every
other alternative antibody tested, whether commercial (Pro-
teintech, catalog number 16219-1-AP; rabbit polyclonal, Santa
Cruz Biotechnology D-15; S14 goat polyclonals, Abcammouse
polyclonal ab69669, and rabbit polyclonal ab90516) or our own
monoclonals, failed to react with endogenous hVam6p in
immunoblots, although these antibodies often recognize the
overexpressed protein. However, it is reassuring to us that the
Piper antibody recognizes endogenous hVam6p coprecipitated
with MCV LT in MCCs and it detects coprecipitated, overex-
pressed hVam6p, which interacts with wild-type MCV LT, but
not the Trp-209 binding mutant. This coprecipitation pattern
closely mirrors what we observe with HA-tagged hVam6p
usingHA antibody. Finally, the immunofluorescence pattern of
nuclear and perinuclear staining observed in MCCs using the
Piper antibody clearly overlaps with what we observe in heter-
ologous cell systems using the tagged hVam6p. Future experi-
ments, involving development of an independent antibody rec-
ognizing endogenous hVam6p, will establish the significance of
the perinuclear localization in MCCs.
Our studies provide the first evidence for cytoplasmic target-
ing of endolysosomal components by a polyomavirus using a
novel nuclear sequestration mechanism. MCV LT provides a
unique reagent to study Vam6/Vps39 functions in cytoplasmic
lysosomal trafficking. Development of robust MCV replication
systemswill allow examination of the consequences of hVam6p
sequestration by LT to MCV infection.
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